Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 5
1995 3
1996 6
1997 4
1998 2
1999 3
2000 1
2001 4
2002 2
2003 5
2004 6
2005 5
2006 6
2007 5
2008 8
2009 3
2010 2
2011 3
2012 9
2013 5
2014 1
2015 2
2016 3
2017 1
2018 2
2019 5
2020 6
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

103 results
Results by year
Filters applied: . Clear all
Page 1
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM. Dillard P, et al. Among authors: florenes va. Mol Ther. 2021 Mar 3;29(3):1199-1213. doi: 10.1016/j.ymthe.2020.11.019. Epub 2020 Nov 17. Mol Ther. 2021. PMID: 33212301 Free article.
Soluble AXL as a marker of disease progression and survival in melanoma.
Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM. Flem-Karlsen K, et al. Among authors: florenes va. PLoS One. 2020 Jan 9;15(1):e0227187. doi: 10.1371/journal.pone.0227187. eCollection 2020. PLoS One. 2020. PMID: 31917795 Free PMC article.
MX 2 is a novel regulator of cell cycle in melanoma cells.
Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A. Juraleviciute M, et al. Among authors: florenes va. Pigment Cell Melanoma Res. 2020 May;33(3):446-457. doi: 10.1111/pcmr.12837. Epub 2019 Nov 13. Pigment Cell Melanoma Res. 2020. PMID: 31660681 Free PMC article.
Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K, McFadden E, Flørenes VA, Davidson B. Flem Karlsen K, et al. Among authors: florenes va. Gynecol Oncol. 2019 Feb;152(2):408-415. doi: 10.1016/j.ygyno.2018.11.012. Epub 2018 Nov 15. Gynecol Oncol. 2019. PMID: 30448261
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.
Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K. Ree AH, et al. Among authors: florenes va. Acta Oncol. 2020 Jul;59(7):733-740. doi: 10.1080/0284186X.2020.1742377. Epub 2020 Mar 25. Acta Oncol. 2020. PMID: 32208873
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.
Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. Flørenes VA, et al. Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13. Transl Oncol. 2019. PMID: 31096111 Free PMC article.
103 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page